Analysts Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) PT at $7.00

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have earned a consensus rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $7.00.

Several brokerages recently commented on RXRX. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. ARK Investment Management LLC grew its stake in Recursion Pharmaceuticals by 7.6% in the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company’s stock worth $184,174,000 after acquiring an additional 2,469,104 shares in the last quarter. Softbank Group CORP. bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $99,152,000. Kinnevik AB publ boosted its stake in shares of Recursion Pharmaceuticals by 12.8% during the first quarter. Kinnevik AB publ now owns 13,434,171 shares of the company’s stock valued at $71,067,000 after purchasing an additional 1,528,503 shares in the last quarter. Novo Holdings A S bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $68,375,000. Finally, Geode Capital Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 20.7% during the second quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company’s stock valued at $39,353,000 after purchasing an additional 1,332,428 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Up 2.3%

Shares of NASDAQ RXRX opened at $5.77 on Wednesday. The firm’s 50-day moving average price is $5.49 and its 200-day moving average price is $5.84. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $2.35 billion, a price-to-earnings ratio of -3.24 and a beta of 0.93. Recursion Pharmaceuticals has a 12-month low of $3.79 and a 12-month high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The business’s revenue for the quarter was up 33.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.40) earnings per share. On average, equities research analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.